Inspire Investing LLC Makes New $258,000 Investment in DexCom, Inc. $DXCM

Inspire Investing LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 2,959 shares of the medical device company’s stock, valued at approximately $258,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Golden State Wealth Management LLC raised its position in shares of DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 264 shares during the period. Zions Bancorporation National Association UT bought a new stake in shares of DexCom during the 1st quarter worth about $27,000. Anderson Financial Strategies LLC acquired a new position in DexCom in the 1st quarter valued at about $37,000. Alpine Bank Wealth Management bought a new position in DexCom in the 1st quarter valued at about $40,000. Finally, Private Trust Co. NA raised its holdings in DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock valued at $46,000 after acquiring an additional 335 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several recent research reports. Truist Financial lowered their price objective on DexCom from $102.00 to $94.00 and set a “buy” rating on the stock in a research report on Wednesday. The Goldman Sachs Group decreased their price target on shares of DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research note on Wednesday, October 1st. Oppenheimer cut shares of DexCom from an “outperform” rating to a “market perform” rating in a research note on Monday, September 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of DexCom in a report on Wednesday, October 8th. Finally, Robert W. Baird decreased their target price on shares of DexCom from $112.00 to $90.00 and set an “outperform” rating on the stock in a research report on Friday, September 26th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $97.00.

Insider Transactions at DexCom

In other DexCom news, EVP Michael Jon Brown sold 500 shares of the firm’s stock in a transaction on Friday, August 15th. The shares were sold at an average price of $80.29, for a total value of $40,145.00. Following the transaction, the executive vice president directly owned 94,102 shares of the company’s stock, valued at approximately $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kyle Malady sold 667 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the transaction, the director owned 22,667 shares in the company, valued at $1,832,853.62. This represents a 2.86% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,849 shares of company stock worth $564,733. Insiders own 0.32% of the company’s stock.

DexCom Price Performance

DXCM stock opened at $66.60 on Friday. The company has a fifty day moving average price of $73.35 and a 200-day moving average price of $77.52. The company has a market capitalization of $26.12 billion, a P/E ratio of 46.25, a PEG ratio of 1.39 and a beta of 1.47. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the firm posted $0.43 EPS. The company’s quarterly revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.